Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test
Sanofi has been hit with a $250 million impairment charge after an E. coli vaccine candidate it was developing together with Johnson & Johnson failed to clear a Phase 3 study. An independent data monitoring ...
Sanofi has been hit with a $250 million impairment charge after an E. coli vaccine candidate it was developing together with Johnson & Johnson failed to clear a Phase 3 study.
An independent data monitoring ...
